Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection

Clinical Infectious Diseases

Volumn 44, Issue 4, 2007, Pages 607-614

  Skiest, Daniel J ^a,g   Vazquez, Jose A ^c   Anstead, Gregory M ^b   Graybill, John R ^b   Reynes, Jacques ^f   Ward, Douglas ^d   Hare, Roberta ^e,h   Boparai, Navdeep ^e   Isaacs, Randi ^e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d Dupont Circle Physician's Group   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f GUI DE CHAULIAC HOSPITAL   (France)

^g BAYSTATE MEDICAL CENTER   (United States)

^h Advanced Biologics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ABDOMINAL PAIN; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASTHENIA; CANDIDA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ENDOSCOPY; EPISTAXIS; ESOPHAGUS CANDIDIASIS; FATIGUE; FEMALE; FLATULENCE; FUNGUS CULTURE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LABORATORY TEST; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OROPHARYNX CANDIDIASIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTHROMBIN TIME; PRURITUS; QT PROLONGATION; RASH; SHORT COURSE THERAPY; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CANDIDIASIS; CANDIDIASIS, ORAL; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, FUNGAL; ESOPHAGEAL DISEASES; FEMALE; FLUCONAZOLE; FOLLOW-UP STUDIES; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; PROBABILITY; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME; TRIAZOLES;

EID: 33846902613     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/511039     Document Type: Article

References (40)

1. Revankar SG, Kirkpatrick WR, McAtee RK, et al. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996; 174:821-7.
2. Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis 1998; 26:259-72.
3. Fichtenbaum CJ, Powderly WG. Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis 1998; 26:556-65.
4. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38:161-89.
5. Sangeorzan JA, Bradley SF, He X, et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994; 97:339-46.
6. Barrett JP, Vardulaki KA, Conlon C, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003; 25:1295-320.
7. Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33:1447-54.
8. Kartsonis NA, Saah A, Lipka CJ, Taylor A, Sable CA. Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study. J Antimicrob Chemother 2004; 53:878-81.
9. Hegener P, Troke PF, Fatkenheuer G, Diehl V, Ruhnke M. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 1998; 12:2227-8.
10. Gerzenshtein L, Patel SM, Scarsi KK, Postelnick MJ, Flaherty JP. Breakthrough Candida infections in patients receiving voriconazole. Ann Pharmacother 2005; 39:1342-5.
11. Alexander BD, Schell WA, Miller JL, Long GD, Perfect JR. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 2005; 80:868-71.
12. Barchiesi F, Arzeni D, Fothergill AW, et al. In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob Agents Chemother 2000; 44:226-9.
13. Herbrecht R. Posaconazole: a potent, extended-spectrum triazole antifungal for the treatment of serious fungal infections. Int J Clin Pract 2004; 58:612-24.
14. Pfaller MA, Messer SA, Hollis RJ, et al. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother 1998; 42:3242-4.
15. Anstead GM, Martinez M, Graybill JR. Control of a Candida glabrata prosthetic endovascular infection with posaconazole. Med Mycol 2006; 273-7.
16. Raad I, Chapman S, Bradsher R, et al. Posaconazole (POS) salvage therapy for invasive fungal infections (IFI) [abstract M-669]. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2004.
17. Tobón A, Correa AL, Arango M, de Bedout C, Restrepo A. Posaconazole therapy for severe abdominal candidiasis: a case report. Rev Iberoam Micol 2004; 21:78-80.
18. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standards. NCCLS document M27-A2. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
19. Migliorati CA, Birman EG, Cury AE. Oropharyngeal candidiasis in HIV-infected patients under treatment with protease inhibitors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98:301-10.
20. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30(Suppl 1):S5-14.
21. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002; 46:451-7.
22. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33:1529-35.
23. Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113:294-9.
24. Kartsonis N, DiNubile MJ, Bartizal K, Hicks PS, Ryan D, Sable CA. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J Acquir Immune Defic Syndr 2002; 31:183-7.
25. Villarreal NC, Fothergill AW, Kelly C, Patterson JE, Rinaldi MG, Patterson TF. Candida glabrata resistance to caspofungin during therapy [abstract M-1034]. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2004.
26. Laverdiere M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006; 57:705-8.
27. Miller CD, Lomaestro BW, Park S, Perlin DS. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 2006; 26:877-80.
28. Cartledge JD, Midgley J, Youle M, Gazzard BG. Itraconazole cyclodextrin solution - effective treatment for HIV-related candidosis unresponsive to other azole therapy [letter]. J Antimicrob Chemother 1994; 33:1071-3.
29. Saag MS, Fessel WJ, Kaufman CA, et al. Treatment of fluconazole- refractory oropharyngeal candidiasis with intraconazole oral solution in HIV-positive patients. AIDS Res Hum Retroviruses 1999; 15:1413-7.
30. Eichel M, Just-Nubling G, Helm EB, Stille W. Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis [in German]. Mycoses 1996; 39:102-6.
31. Phillips P, Zemcov J, Mahmood W, Montaner JS, Craib K, Clarke AM. Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. AIDS 1996; 10:1369-76.
32. Vazquez JA. Options for the management of mucosal candidiasis in patients with AIDS and HIV infection. Pharmacotherapy 1999; 19:76-87.
33. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter, randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006; 42:1179-86.
34. Heimark L, Shipkova P, Greene J, et al. Mechanism of azole antifungal activity as determined by liquid chromatographic/mass spectrometric monitoring of ergosterol biosynthesis. J Mass Spectrom 2002; 37:265-9.
35. Li X, Brown N, Chau AS, et al. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother 2004; 53:74-80.
36. Xiao L, Madison V, Chau AS, Loebenberg D, Palermo RE, McNicholas PM. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14α-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother 2004; 48:568-74.
37. Chau AS, Mendrick CA, Sabatelli FJ, Loebenberg D, McNicholas PM. Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother 2004; 48:2124-31.
38. Sanglard D, Ischer F, Bille J. Interactions of the azole SCH56592 with Candida albicans multidrug transporters and different cytochrome P450 forms [abstract 51]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto, Ontario). Washington, DC: American Society for Microbiology, 1997.
39. Meyer M. Palliative care and AIDS: 2 - gastrointestinal symptoms. Int J STD AIDS 1999; 10:495-505.
40. Volberding PA, Baker KR, Levine AM. Human immunodeficiency virus hematology. Hematology Am Soc Hematol Educ Program 2003; 294-313.